Crinetics Pharmaceuticals IncNASDAQ:CRNX
- LAST PRICE50.4500
- TODAY'S CHANGE (%)1.0700 (2.1669%)
- Bid / Lots50.3400/ 4
- Ask / Lots50.6200/ 4
- Open / Previous Close50.3300 / 49.3800
- Day Range
- 52 Week Range
- Volume322,964
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CRNX |
|---|---|---|
| 09:32 ET | 5243 | 50.32 |
| 09:34 ET | 300 | 50.95 |
| 09:36 ET | 770 | 50.93 |
| 09:38 ET | 1238 | 51.01 |
| 09:39 ET | 600 | 51.18 |
| 09:41 ET | 2589 | 51.01 |
| 09:43 ET | 8290 | 50.65 |
| 09:45 ET | 1413 | 50.55 |
| 09:48 ET | 1691 | 50.525 |
| 09:50 ET | 10001 | 50.535 |
| 09:52 ET | 1400 | 50.39 |
| 09:54 ET | 3188 | 50.38 |
| 09:56 ET | 1300 | 50.38 |
| 09:57 ET | 40428 | 50.38 |
| 09:59 ET | 6735 | 50.385 |
| 10:01 ET | 2648 | 50.19 |
| 10:03 ET | 4697 | 50.205 |
| 10:06 ET | 24421 | 50.12 |
| 10:08 ET | 959 | 50.2 |
| 10:10 ET | 106068 | 50.2 |
| 10:12 ET | 2895 | 50.2 |
| 10:14 ET | 1555 | 50.2 |
| 10:15 ET | 3911 | 50.25 |
| 10:17 ET | 4607 | 50.185 |
| 10:19 ET | 200 | 50.25 |
| 10:21 ET | 485 | 50.1415 |
| 10:24 ET | 8064 | 50.17 |
| 10:26 ET | 8653 | 50.275 |
| 10:28 ET | 900 | 50.13 |
| 10:30 ET | 497 | 50.1 |
| 10:32 ET | 16193 | 50.12 |
| 10:33 ET | 400 | 50.16 |
| 10:35 ET | 842 | 50.2 |
| 10:37 ET | 4072 | 50.145 |
| 10:39 ET | 200 | 50.15 |
| 10:42 ET | 3912 | 50.2 |
| 10:44 ET | 600 | 50.2025 |
| 10:46 ET | 6558 | 50.425 |
| 10:48 ET | 1574 | 50.45 |
Yesterday
DJ Crinetics Pharmaceuticals Price Target Maintained With a $65.00/Share by Cantor Fitzgerald, from 8:55AM ET on Tuesday May 14, 2024 by Dow Jones
8:55AM ET on Tuesday May 14, 2024 by Dow Jones
May 10, 2024
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), from 5:38PM ET on Friday May 10, 2024 by Dow Jones
5:38PM ET on Friday May 10, 2024 by Dow JonesDJ Crinetics Pharmaceuticals Price Target Maintained With a $60.00/Share by HC Wainwright & Co., from 3:50PM ET on Friday May 10, 2024 by Dow Jones
3:50PM ET on Friday May 10, 2024 by Dow JonesDJ Crinetics Pharmaceuticals Price Target Maintained With a $80.00/Share by JMP Securities, from 12:55PM ET on Friday May 10, 2024 by Dow Jones
12:55PM ET on Friday May 10, 2024 by Dow Jones
May 9, 2024
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update, from 4:06PM ET on Thursday May 09, 2024 by Dow Jones
4:06PM ET on Thursday May 09, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Crinetics Pharmaceuticals Inc | 3.9B | -13.4x | --- |
Nuvalent Inc | 4.4B | -29.5x | --- |
Immunovant Inc | 4.4B | -17.2x | --- |
Summit Therapeutics Inc | 3.3B | -3.0x | --- |
Biohaven Ltd | 3.3B | -5.7x | --- |
Madrigal Pharmaceuticals Inc | 4.5B | -9.3x | --- |
Company Information
Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its Paltusotine, an investigational, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It has demonstrated pharmacologic proof-of-concept in a Phase 1 clinical study for CRN04894, an investigational, oral ACTH antagonist, that is in Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing's disease. Its drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including other programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves' disease, thyroid eye disease, diabetes and obesity.
Contact Information
- Headquarters
- 10222 Barnes Canyon Rd Bldg 2SAN DIEGO, CA, United States 92121-2711
- Phone
- 858-450-6464
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Wendell Wierenga
- Co-Founder, Director
- R. Scott Struthers
- Co-Founder, Chief Scientific Officer
- Stephen Betz
- Chief Financial Officer
- Marc Wilson
- Chief Operating Officer
- Jeff Knight
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.9B |
|---|---|
Revenue (TTM) | $2.0M |
Shares Outstanding | 78.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.67 |
EPS | $-3.77 |
Book Value | $7.91 |
P/E Ratio | -13.4x |
Price/Sales (TTM) | 1,969.8 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -12,571.38% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
